Investigational Drug Information for CTP-692
✉ Email this page to a colleague
What is the drug development status for CTP-692?
CTP-692 is an investigational drug.
There have been 4 clinical trials for CTP-692.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 26th 2019.
The most common disease conditions in clinical trials are Schizophrenia and [disabled in preview]. The leading clinical trial sponsors are Concert Pharmaceuticals, Cognitive Research Corporation, and [disabled in preview].
Summary for CTP-692
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 6 |
| WIPO Patent Applications | 1 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2019-11-26) |
| Vendors | 6 |
Recent Clinical Trials for CTP-692
| Title | Sponsor | Phase |
|---|---|---|
| A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia | Cognitive Research Corporation | Phase 2 |
| A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia | Concert Pharmaceuticals | Phase 2 |
| Multiple Ascending Dose Study of CTP-692 in Healthy Volunteers | Concert Pharmaceuticals | Phase 1 |
Clinical Trial Summary for CTP-692
Top disease conditions for CTP-692
Top clinical trial sponsors for CTP-692
US Patents for CTP-692
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
